Search results for " arthritis"

showing 10 items of 629 documents

Eye Pain and Dry Eye in Patients with Fibromyalgia.

2018

Objectives The aim of this study was to examine visual function and eye symptoms in fibromyalgia patients, with a particular focus on dry eye syndrome and eye pain. Methods A tertiary care center-based cross-sectional study was carried out in chronic musculoskeletal pain patients diagnosed with fibromyalgia. Chronic musculoskeletal pain patients without fibromyalgia were enrolled as a comparison group. Self-reported eye pain was investigated with the McGill pain questionnaire and the numeric rating scale. In addition, we assessed corrected visual acuity, vision-related quality of life, and self-reported dry eye syndrome. Results A total of 90 musculoskeletal pain patients were included, wit…

AdultMalemedicine.medical_specialtyVisual acuityFibromyalgiagenetic structuresCross-sectional studyDry Eye Syndromes03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineFibromyalgiamedicinePrevalenceEye PainHumans030203 arthritis & rheumatologybusiness.industryChronic painGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesRheumatologyAnesthesiology and Pain MedicineCross-Sectional StudiesMcGill Pain Questionnaire030221 ophthalmology & optometryPhysical therapyQuality of LifeDry Eye SyndromesFemaleNeurology (clinical)medicine.symptomChronic PainbusinessPain medicine (Malden, Mass.)
researchProduct

Comparative, validity and responsiveness of the HOOS-PS and KOOS-PS to the WOMAC physical function subscale in total joint replacement for Osteoarthr…

2009

Udgivelsesdato: 2009-Jul OBJECTIVE: To evaluate the internal consistency of the Hip disability and Osteoarthritis Outcome Score-Physical Function Short-form (HOOS-PS) and the Knee injury and Osteoarthritis Outcome Score-Physical Function Short-form (KOOS-PS) in total hip replacement (THR) and total knee (TKR) replacement. Construct validity and responsiveness were compared to the Western Ontario McMaster Universities' Osteoarthritis Index (WOMAC) Likert 3.0 physical function (PF) subscale and the PF excluding the items in the short measures (PF-exclusions). METHODS: Participants completed the full HOOS or KOOS, measures of fatigue, anxiety, depression and the Chronic Pain Grade (CPG) pre-su…

AdultMalemedicine.medical_specialtyWOMACmedicine.medical_treatmentArthroplasty Replacement HipBiomedical EngineeringOsteoarthritisAnxietySeverity of Illness IndexOsteoarthritis HipValidity03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationRheumatologyCronbach's alphaSeverity of illnessActivities of Daily LivingmedicineHumansOrthopedics and Sports MedicineDisabled PersonsArthroplasty Replacement KneeHOOS-PSFatigueTotal joint replacementAgedPain Measurement030203 arthritis & rheumatologyAged 80 and over030222 orthopedicsDepressive Disorderbusiness.industryChronic painConstruct validityResponsivenessMiddle AgedOsteoarthritis Kneemedicine.diseaseKOOS-PSArthroplastyArthralgiaWOMACPhysical therapyAnxietyFemalemedicine.symptombusinessOsteoarthritis and Cartilage
researchProduct

Aerobic exercise for axial spondyloarthritis - its effects on disease activity and function as compared to standard physiotherapy: A systematic revie…

2019

Aim To evaluate the impact of an aerobic fitness program on disease activity, defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and on C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and the Bath Ankylosing Spondylitis Functional Index (BASFI) in case of axial spondyloarthritis. Methods A systematic review of the literature, following the Prisma recommendations, was performed by two reviewers on the PubMed and Embase databases. Controlled trials assessing the efficacy of aerobic exercises compared to physiotherapy on axial spondyloarthritis disease activity were included. The diagnosis of axial spondyloarthritis was meeting the New York criteria and/o…

AdultMalemedicine.medical_specialty[SDV]Life Sciences [q-bio]Severity of Illness Index03 medical and health sciences0302 clinical medicineRheumatologySpondylarthritisHeart rateHumansMedicineAerobic exerciseSpondylitis Ankylosing030212 general & internal medicineAxial spondyloarthritisBASDAIPhysical Therapy ModalitiesComputingMilieux_MISCELLANEOUS030203 arthritis & rheumatologyAnkylosing spondylitismedicine.diagnostic_testbusiness.industryRecovery of FunctionMiddle Agedmedicine.diseaseExercise Therapy3. Good healthTreatment OutcomeErythrocyte sedimentation rateMeta-analysisPhysical therapyFemalebusinessBASFIInternational Journal of Rheumatic Diseases
researchProduct

The relationship between demographic- and disease-related variables and health-related quality of life in patients with axial spondyloarthritis

2017

Background Axial spondyloarthritis (ax-SpA) is a chronic inflammatory disease of the spine causing pain, stiffness, loss in physical function, and fatigue. Therefore, the physical and psychological burden of having this chronic disease can reduce the quality of life. We aimed to explore the relationship between demographic- and disease-related variables and health-related quality of life (HRQoL) in patients with ax-SpA. Methods Demographic- and disease-related, HRQoL-related and treatment data were collected. Disease measures included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the BAS Functional Index (BASFI), the BAS Global (BAS-G) score, the Maastricht Ankylosing Spo…

AdultMalemedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemSports medicineHealth-related quality of lifeUtility measures03 medical and health sciences0302 clinical medicineRheumatologyQuality of lifeInternal medicineSpondylarthritisEpidemiologymedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineAxial spondyloarthritisBASDAIExerciseAged030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryEnthesitisMiddle Agedmedicine.diseaseRheumatologyQuality of LifePhysical therapyFemaleTargeted medicationsmedicine.symptomlcsh:RC925-935BASFIbusinessResearch Article
researchProduct

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

2018

Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…

AdultMalemedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPopulationImmunologyPlaceboAntibodies Monoclonal HumanizedGastroenterologySystemic Lupus ErythematosusSeverity of Illness Index03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineeducationAdverse effectskin and connective tissue diseases030203 arthritis & rheumatologyeducation.field_of_studyLupus erythematosusIntention-to-treat analysisbusiness.industryComplement C3DNAmedicine.diseaseBelimumabRheumatologyIntention to Treat AnalysisTreatment OutcomeAntibodies AntinuclearImmunology and Allergy; Rheumatology; ImmunologyCorticosteroidOriginal ArticleFemalebusinessmedicine.drug
researchProduct

Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd: YAG low-level laser …

2013

Objective: Trauma during dental surgery is a predisposing factor for bisphosphonates (BP)-related osteonecrosis of the jaws (BRONJ). However, about 40% of cases of BRONJ are not related to dental invasive procedures, being probably associated to endodontic or periodontal infections. Extraction of non-treatable teeth is considered a reliable choice, to improve symptoms and to reduce the risk of BRONJ. Here we report our experience of tooth extractions in patients under oral or intravenous BP therapy. Study Design: Two-hundred and seventeen patients (38 males, 179 females; mean age 68.72 ± 11.26 years, range 30 to 83 years) under BP therapy received 589 tooth extractions at the Unit of Oral M…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentOsteoporosisAntibioticsDentistryOdontologíaLasers Solid-StatePostoperative ComplicationsClinical ProtocolsmedicineHumansLow-Level Light TherapyDental CareGeneral DentistryMultiple myelomaLow level laser therapyAgedAged 80 and overBisphosphonate-associated osteonecrosis of the jawDiphosphonatesbusiness.industryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgerystomatognathic diseasesOtorhinolaryngologyRheumatoid arthritisDental surgeryTooth ExtractionUNESCO::CIENCIAS MÉDICASResearch-ArticleBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryOral SurgerybusinessOral medicine
researchProduct

Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.

2002

Abstract Background: Psoriatic skin lesions in patients with Crohn's disease or psoriatic arthritis have shown improvement during infliximab treatment. Objective: The purpose of our study was to systematically assess the effects of infliximab in patients with psoriatic skin lesions. Methods: Eight patients with severe psoriasis were enrolled in an open-label clinical trial. Patients received infliximab, 5 mg/kg, intravenously at weeks 0, 2, and 6. The Psoriasis Area and Severity Index (PASI) was used to monitor disease activity at weeks 0, 2, 4, 6, 8, 10, and 14. Week 10 was the end point of the treatment phase; week 14 was the follow-up end point. Pruritus was assessed on a scale of 0 to 3…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAcanthosisDermatologyGastroenterologySeverity of Illness IndexPsoriatic arthritisPsoriasis Area and Severity IndexInternal medicinePsoriasisBiopsymedicineHumansPsoriasisAdverse effectInfusions IntravenousChemotherapymedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabSurgeryTreatment OutcomeFemaleDermatologic Agentsbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct

Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Ita…

2018

Objective.Macrophage activation syndrome (MAS) is a reactive form of hemophagocytic lymphohistiocytosis, which can complicate adult-onset Still disease (AOSD). We investigated AOSD clinical features at the time of diagnosis, to assess predictors of MAS occurrence. Further, we analyzed the outcomes of patients with AOSD who experience MAS.Methods.Patients with AOSD admitted to any Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale center were retrospectively analyzed for features typical of AOSD, MAS occurrence, and their survival rate.Results.Of 119 patients with AOSD, 17 experienced MAS (12 at admission and 5 during followup). Twelve patients with MAS at first admission diff…

AdultMalemusculoskeletal diseases0301 basic medicineAdult onset still diseasemedicine.medical_specialtyAbdominal painMultivariate analysisSurvivalImmunologyStill DiseaseComorbidityGastroenterology03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinePrevalencemedicineHumansImmunology and AllergySurvival rateRetrospective Studies030203 arthritis & rheumatologyFerritinHemophagocytic lymphohistiocytosisbiologybusiness.industryIncidencefungiMiddle AgedHyperferritinemic syndromemedicine.diseaseSurvival RateFerritin030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeFerritinsCohortbiology.proteinAdult onset still disease; Ferritin; Hyperferritinemic syndrome; Macrophage activation syndrome; Survival; Rheumatology; Immunology and Allergy; ImmunologyFemalemedicine.symptombusinessStill's Disease Adult-OnsetThe Journal of Rheumatology
researchProduct

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 case…

2016

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significan…

AdultMalemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyImmunologyAdult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome; Adult; Ambulatory Care Facilities; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Immunology and Allergy; ImmunologyDiseaseAmbulatory Care FacilitiesAutoimmune Diseases03 medical and health sciences0302 clinical medicineAdult onset Still's diseaseInternal medicineHumansImmunology and AllergyMedicineRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseaseAdult patientsbusiness.industryMortality ratefungiRetrospective cohort studyMiddle AgedPrognosisHyperferritinemic syndromemedicine.diseasebody regionsSettore MED/16 - ReumatologiaTreatment Outcome030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeCohortImmunologyFemalelipids (amino acids peptides and proteins)businessCytokine stormImmunosuppressive Agentshormones hormone substitutes and hormone antagonistsAutoimmunity Reviews
researchProduct

IL 10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients.

2001

Objective To investigate the association of microsatellites and single-nucleotide promoter polymorphisms (SNPs) in the gene for the cytokine interleukin-10 (IL-10) with susceptibility to and outcome of reactive arthritis (ReA). Methods From genomic DNA, IL-10 microsatellites G and R and IL-10 promoter polymorphisms at positions −1087 and −524 were typed by polymerase chain reaction, automated fragment length analysis, and restriction fragment digestion in 85 Finnish patients with ReA and 62 HLA–B27–positive Finnish controls. ReA patients had been followed up for 20 years. Genotypes and haplotypes of IL-10 were correlated with distinct features of the disease course, such as triggering agent…

AdultMalemusculoskeletal diseasesGenetic LinkageImmunologySingle-nucleotide polymorphismArthritis ReactivePolymorphism Single NucleotideRestriction fragmentRheumatologyProhibitinsGenotypeHumansImmunology and AllergyPharmacology (medical)AllelePromoter Regions GeneticAllele frequencyFinlandGeneticsbiologyreactive arthritis IL-10 microsatellites polymorphismHaplotypeMiddle AgedInterleukin-10HaplotypesImmunologybiology.proteinMicrosatelliteFemaleRestriction fragment length polymorphismFollow-Up StudiesMicrosatellite Repeats
researchProduct